The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
What Are The Forecasted Market Size Figures For The Lisinopril Market In 2026 And 2030?
The lisinopril market has seen substantial growth over recent years. This market is projected to expand from $1.87 billion in 2025 to $1.99 billion in 2026, achieving a compound annual growth rate (CAGR) of 6.2%. The historical growth can be linked to factors such as the increasing prevalence of hypertension, broad clinical adoption of ACE inhibitors, an expanding aging demographic, its early application in heart failure management, and enhanced access to primary healthcare.
The lisinopril market size is projected for substantial expansion over the upcoming years, expected to reach $2.47 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 5.5%. This growth throughout the forecast period is driven by factors such as the increasing burden of cardiovascular disease, a rising demand for affordable generic drugs, a heightened focus on preventive cardiac care, the widening scope of treatment for diabetic kidney disease, and increased healthcare spending on chronic disease management. Significant trends anticipated for this period include the escalating prevalence of hypertension and cardiovascular disorders, an increasing reliance on ACE inhibitors for first-line therapy, the expansion of generic lisinopril prescriptions, its growing application in post-heart attack management, and improved long-term treatment adherence in chronic care.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=16465&type=smp
Which Strategic Drivers Are Supporting The Lisinopril Market Development?
The increasing occurrence of cardiovascular conditions is anticipated to stimulate the expansion of the lisinopril market in the future. Cardiovascular diseases (CVDs) refer to various ailments that impact the heart and circulatory system. This rise in cardiovascular disease prevalence is attributable to multiple elements, including an aging and expanding global population, various predisposing factors, and insufficient application of established prevention and treatment protocols. Lisinopril plays a key role in managing cardiovascular diseases, mainly by its efficacy in lowering blood pressure and alleviating stress on the heart and kidneys. Its mechanism involves suppressing angiotensin II production, leading to the widening of blood vessels, a decrease in blood volume, and safeguarding organs from harm. For example, data from the Singapore Heart Foundation (SHF), a Singapore-based non-profit organization, reported 5,302 deaths from ischemic heart diseases in May 2024, marking a small increase from 5,290 deaths in 2022. Thus, the escalating prevalence of cardiovascular diseases is fueling the expansion of the lisinopril market.
Which Segment Divisions Form The Structure Of The Lisinopril Market?
The lisinopril market covered in this report is segmented –
1) By Brand: Prinivil, Zestril, Other Brands
2) By Disease: Hypertension, Heart Failure, Heart Attack
3) By Dosage: Tablet, Liquid
4) By End-Users: Hospitals, Specialty Clinics
Subsegments:
1) By Prinivil: Different Dosage Forms, Generic Versions Of Prinivil
2) By Zestril: Different Dosage Forms, Generic Versions Of Zestril
3) By Other Brands: International Brand Variants, Combination Drug Formulations
Which Companies Are Engaged In The Lisinopril Market Environment?
Major companies operating in the lisinopril market are Merck & Co. Inc., Pfizer Inc., Viatris Inc., Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Limited, Aurobindo Pharma Ltd., Cipla Inc., Hikma Pharmaceutical Plc, Apotex Inc., Amneal Pharmaceutical Inc., Lupin Ltd., Zydus Cadila Healthcare Ltd., Hetero Ltd., Dr. Reddy’s Laboratories Ltd., Torrent Pharmaceuticals Ltd., Alembic Pharmaceuticals Ltd., Glenmark Pharmaceuticals Ltd., Intas Pharmaceuticals Ltd., Mylan Pharmaceuticals Inc., Accord Healthcare Ltd., Sandoz International GmbH
Access The Complete Lisinopril Market Report:
https://www.thebusinessresearchcompany.com/report/lisinopril-global-market-report
Which Region Leads The Lisinopril Market By Size?
North America was the largest region in the lisinopril market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the lisinopril market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access Lisinopril Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/customise?id=16465&type=smp
Browse Through More Reports Similar to the Global Lisinopril Market 2026, By The Business Research Company
Liraglutide Global Market Report 2026
https://www.thebusinessresearchcompany.com/report/liraglutide-global-market-report
Lithium Global Market Report 2026
https://www.thebusinessresearchcompany.com/report/lithium-global-market-report
Lithium Ion Li Ion Batteries Global Market Report 2026
https://www.thebusinessresearchcompany.com/report/lithium-ion-li-ion-batteries-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model